CN113171424B - 一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 - Google Patents
一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 Download PDFInfo
- Publication number
- CN113171424B CN113171424B CN202110517975.1A CN202110517975A CN113171424B CN 113171424 B CN113171424 B CN 113171424B CN 202110517975 A CN202110517975 A CN 202110517975A CN 113171424 B CN113171424 B CN 113171424B
- Authority
- CN
- China
- Prior art keywords
- liver
- preparation
- mcd
- extract
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 96
- 230000008021 deposition Effects 0.000 title claims abstract description 45
- 150000002632 lipids Chemical class 0.000 title claims abstract description 43
- 241000282326 Felis catus Species 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 241000282472 Canis lupus familiaris Species 0.000 title claims description 18
- 239000000284 extract Substances 0.000 claims abstract description 45
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 14
- 229930182817 methionine Natural products 0.000 claims abstract description 14
- 241001083548 Anemone Species 0.000 claims abstract description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001231 choline Drugs 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000002390 rotary evaporation Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 241000249864 Tussilago Species 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000000273 veterinary drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 58
- 241000699670 Mus sp. Species 0.000 abstract description 35
- 210000005228 liver tissue Anatomy 0.000 abstract description 25
- 210000002966 serum Anatomy 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 15
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 13
- 241000282465 Canis Species 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 239000009606 Bidens pilosa plant extract Substances 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 18
- 108010082126 Alanine transaminase Proteins 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 229940118019 malondialdehyde Drugs 0.000 description 10
- 208000000501 Lipidoses Diseases 0.000 description 9
- 206010024585 Lipidosis Diseases 0.000 description 9
- 241000485481 Petasites hybridus Species 0.000 description 9
- 235000001436 butterbur Nutrition 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 description 9
- 241000282324 Felis Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000010706 fatty liver disease Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- -1 flavone lignan compounds Chemical class 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 241001442052 Symphytum Species 0.000 description 5
- 235000005865 Symphytum officinale Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 230000006372 lipid accumulation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000004481 Choline Deficiency Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000021752 choline deficiency disease Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 210000002989 hepatic vein Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000013424 sirius red staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Chemical class 0.000 description 2
- 239000001648 tannin Chemical class 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000446281 Eschenbachia blinii Species 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 244000308505 Filipendula ulmaria Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000071956 Graptopetalum paraguayense Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000293861 Scrophularia nodosa Species 0.000 description 1
- 241001263603 Stellera Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002445 liver protective agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 150000004831 organic oxygen compounds Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法。所述中兽药制剂是由风柜斗草提取物250‑500 mg、蛋氨酸15‑25 mg、胆碱15‑25 mg、VB1 5‑10 mg、VB2 5‑10 mg、VB6 5‑10 mg、VB12 5μg混合而成。本发明将风柜斗草提取物同维生素、氨基酸等营养成分复配后获得中兽药制剂，对临床猫肝脂沉积症有治疗作用且作用效果良好，可以显著改善肝脂沉积症小鼠血清ALT、AKP活力水平，显著改善肝组织GSH‑PX活力水平及MDA含量，显著改善肝组织的脂肪变性、炎症反应以及肝脏纤维化。
Description
技术领域
本发明属于中兽药制剂技术领域，具体涉及一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法。
背景技术
猫肝脂沉积症(Feline hepatic lipidosis,FHL)，是在猫临床中最常见的肝脏疾病，又可称猫脂肪肝病。猫肝脂沉积症特点是80％以上的肝细胞中累积了超过正常量甘油三酯，使肝脏的总重量增加50％以上，继发肝功能损害、肝炎、肝脏纤维化、肝内胆汁淤积、肝硬化等。自然发生的猫肝脏脂质沉积症的病史、体格检查和临床病理报告中表明这是一种有许多致病因素的综合征。
FHL分为原发性与继发性。食物供应减少、食物不可口或某些应激原因使动物进食减少，最终导致的厌食而引起的肝脏脂质沉积称为原发性FHL。继发性脂质沉积发生在那些由于潜在疾病而导致厌食症的动物身上。约95％的FHL病例是继发性肝脏脂质沉积。与猫肝脏脂质沉积症相关的疾病很多，包括糖尿病、胰腺炎、炎性肝胆疾病、胃肠道疾病、肾衰竭和肿瘤。
猫脂肪肝是临床中最常见的肝胆疾病之一，严重至肝硬化和肝癌可导致死亡。其近些年来日趋普遍的发病趋势严重威胁到宠物的生命健康以及生活质量。猫肝脏脂质沉积症通常以胆红素浓度升高，血清中碱性磷酸酶(ALP)和丙氨酸氨基转移酶(ALT)活性升高为特征。猫肝脏脂质沉积症的诊断基于患猫的病史、临床表现、临床病理和肝脏的超声结果。患有肝脏脂质沉积症猫的肝脏超声出现肿大和弥漫性高回声，超声诊断猫肝脏脂质沉积症的准确率为70％。
犬肝脏脂质沉积症是指肝脏中的脂肪含量超过肝脏总重量的5％时，或显微镜观察肝脏切片每单位面积上有超过1/3的肝细胞发生了脂肪变性，使机体能量代谢发生紊乱引起肝内中性脂肪蓄积过量的一种病理状态。该病变的发生发展过程包括单纯性脂肪肝，肝纤维化，肝硬化或同时发生或单一发生，病变后期可出现肝功能障碍以及门静脉高压，最终会导致肝性脑病、上消化道出血等并发症死亡。值得注意的是，犬单纯性的脂肪肝在临床上的病例并不多见，大部分犬肝脏脂质沉积症都是在发生肝炎、肝脏纤维化与肝硬化的时候被诊断出来。犬肝脏脂质沉积症多继发于糖尿病、胰腺炎、肿瘤等疾病。
随着人们生活水平的提高以及生活条件的变化，伴侣宠物在人们的日常生活中变得越来越重要，同时也使伴侣宠物的生活水平及生活条件发生了很大的改变，很多家庭给与宠物的日粮能量水平与宠物的日常活动量一定程度上不能达成一个动态平衡。因此近些年来伴侣宠物的肝脏脂质沉积症也愈演愈烈，肝脏脂质沉积症不只是单纯的肝脏类疾病，长期的肝脏脂肪沉积会导致全身各个器官的代谢紊乱，对宠物的生活质量以及寿命产生许多的不利影响。
目前国内对治疗肝脏脂质沉积症应用的天然植物较少且价格昂贵，需进口。水飞蓟素为其中一种，属于黄酮木酯素类化合物。
风柜斗草是被民间广为验证其具有治疗急慢性肝炎价值的中草药，因此其作为一种保肝护肝、治疗肝炎的单验方在民间广为流传使用。同时通过查阅相关文献发现其具有改善非酒性性脂肪肝的作用，因此风柜斗草在治疗宠物肝脏脂质沉积症上具有很大的潜力，但很多研究仍然尚在初期。
发明内容
本发明的目的在于提供一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法。
为实现上述目的，本发明采用的技术方案为：
一种治疗犬猫肝脂沉积症的中兽药制剂，其由以下重量份的原料组成(以5Kg体重犬猫计)：
风柜斗草提取物 250-500mg；
蛋氨酸 15-25mg；
胆碱 15-25mg；
VB1 5-10mg；
VB2 5-10mg；
VB6 5-10mg；
VB12 5ug。
进一步地，所述中兽药制剂由以下重量份的原料组成：
风柜斗草提取物 250-500mg；
蛋氨酸 20mg；
胆碱 20mg；
VB1 5mg；
VB2 5mg；
VB6 5mg；
VB12 5μg。
所述的治疗犬猫肝脂沉积症的中兽药制剂的制备方法，包括以下步骤：
1)将风柜斗草粉碎过50目筛，取风柜斗草粉100g，用20-25倍水浸泡升温至70℃后超声萃取2-2.5h，抽滤泵抽滤收集一次滤液；滤渣用20-25倍水重复操作一次，收集二次滤液；合并一次滤液和二次滤液并负压旋转蒸发浓缩至10-15mL，冷却至室温，加入无水乙醇至乙醇含量为70％，抽滤泵抽滤得上清，将上清负压旋转蒸发浓缩，分装，冷冻干燥，即得到风柜斗草提取物，-80℃保存；
2)将风柜斗草提取物和蛋氨酸、胆碱、VB1、VB2、VB6、VB12按比例混合，得到所述治疗犬猫肝脂沉积症的中兽药制剂。
本发明通过分析风柜斗草提取物对蛋氨酸胆碱缺乏(MCD)饮食诱导肝脂沉积症小鼠肝脏脂质沉积和肝脏纤维化情况的改善情况，进一步探究该药物治疗肝脂沉积症的作用与机制，同时将其同维生素、氨基酸等营养成分复配后应用于临床猫肝脂沉积症观察其治疗效果，为该药在宠物临床中的开发与应用奠定基础。本发明的中兽药制剂，对临床猫肝脂沉积症有治疗作用且作用效果良好，可以显著改善肝脂沉积症小鼠血清ALT、AKP活力水平，显著改善肝组织GSH-PX活力水平及MDA含量，显著改善肝组织的脂肪变性、炎症反应以及肝脏纤维化。
附图说明
图1为风柜斗草提取物的正离子流图。
图2为风柜斗草提取物的负离子流图。
图3为风柜斗草提取物对MCD模型小鼠血清中AKP、ALT、AST活力水平的影响；与MCS组相比，***P<0.001；与MCD组相比，#P<0.05，##P<0.01，SNE(风柜斗草提取物)。
图4为风柜斗草提取物对MCD模型小鼠肝组织中GSH-PX和SOD活力水平及MDA含量的影响；与MCS组相比，***P<0.001；与MCD组相比，#P<0.05，##P<0.01，SNE(风柜斗草提取物)。
图5为风柜斗草提取物对MCD模型小鼠肝脏HE染色切片(100倍)脂质积聚以及炎症簇的影响；↑指向炎症簇；SNE(风柜斗草提取物)。
图6为风柜斗草提取物对MCD模型小鼠肝脏HE染色切片(400倍)脂质积聚以及炎症簇的影响；↑指向炎症簇；SNE(风柜斗草提取物)。
图7为风柜斗草提取物对MCD模型小鼠肝脏天狼星红染色切片(200倍)肝纤维化的影响；SNE(风柜斗草提取物)。
图8为实施例2的六例病例初次B超检查结果。
图9为风柜斗草提取物治疗六例猫脂肪肝病例治疗前与治疗后四次检查结果折线图。
图10为风柜斗草提取物治疗六例猫脂肪肝治疗前后B超影像对比图。
具体实施方式
以下结合具体实施方式对本发明进行详细说明。
实施例1
风柜斗草提取物的制备
风柜斗草粉碎过50目筛，取风柜斗草粉100g，用20倍蒸馏水浸泡升温至70℃后60Hz频率超声萃取2h，抽滤泵抽滤收集滤液，滤渣用20倍水重复操作一次，全部滤液负压旋转蒸发浓缩至10-15mL，冷却至室温，加入无水乙醇至70％醇含量，抽滤泵抽滤得上清，负压旋转蒸发浓缩，分装，冷冻干燥，-80℃保存。
风柜斗草提取物成分分析结果如下：
(1)采用液相色谱质谱联用技术(LC-MS)检测风柜斗草提取物中小分子化合物，对物质进行分离和鉴定，结合质谱数据库信息注释和分类，精准定性，详细的描述提取物中的物质组成和含量，从而达到对其进行定性定量分析的目的。风柜斗草提取物全谱分析谱图见图1、图2。
根据全谱鉴定结果可知：风柜斗草提取物所含物质包括黄酮类化合物、肉桂酸及其衍生物、羧酸及其衍生物、香豆素及其衍生物、脂肪酰类脂质化合物、吲哚及其衍生物、内酯、有机碳酸及其衍生物、有机氮化合物、有机氧化合物、单宁、异戊烯醇酯类脂质化合物、类固醇和类固醇衍生物、喹啉及其衍生物、吡啶及其衍生物、芪类、磺酰基等；同时根据谱图的分析结果可以得出其中黄酮类化合物(物质相对浓度5483.28μg/mL)、单宁(物质相对浓度807.77μg/mL)含量较丰富。
(2)检测三种主要物质的检测含量，总黄酮(以芦丁计)占比为2.11％，总多糖(以葡萄糖计)占比为22％，总皂苷(以人参皂苷Re计)占比为2.87％。
实施例2
风柜斗草提取物改善MCD鼠粮诱导小鼠肝脂沉积症的作用
MCD(蛋氨酸胆碱缺乏)鼠粮饲喂小鼠导致的肝脂沉积症是研究肝脂沉积症常用的动物模型之一，同时MCD鼠粮饲喂小鼠导致的肝脂沉积症与临床中FHL(猫脂肪肝)的发病过程相似，故选择该模型作为探究风柜斗草提取物改善肝脏脂质沉积症的作用的实验动物模型。
1.1实验材料
1.1.1实验动物与MCD、MCS饲料
C57BL/6小鼠购于上海斯莱克实验动物中心。实验按照龙岩学院动物保护与使用委员会批准的实验方案和指南进行。MCD、MCS鼠粮购自睿迪生物科技(深圳)有限公司。鼠粮成分配比见表1。
表1饲料成分
1.1.2实验试剂
表2试验所用试剂材料
1.1.3实验分组
购买4周龄C57BL/6雄性小鼠，体重20g左右，分笼饲养于一个特定的无病原体动物设施中，温度为23℃，湿度为60％，在12h/12h的光/暗循环中，自由获得食物和水，适应一周。
将小鼠随机分为6组，分别为MCS组、MCS+高剂量风柜斗草提取物组、MCD组以及MCD+风柜斗草提取物低、中、高剂量组，每组10只。对照小组给予MCS饮食，其余小组给予MCD饮食；提取物组小鼠按低(100mg/Kg)、中(200mg/Kg)、高(400mg/Kg)灌胃(溶剂为纯净水)，正常对照组和模型组小鼠均灌胃纯净水。每日灌胃一次总体积为0.1mL的风柜斗草提取物，均给予自由饮水，再给予饲料之后，每日观察毛发、饮食、活动和精神状况，每三天记录一次体重以及采食量，连续6周。
最后一次给药后，各组小鼠均禁食、不禁水12h，摘取一侧眼球进行采血，每只采取0.5mL以上的血液样本。取血后，颈部脱臼致死，进行解剖，剥离完整的肝脏，用生理盐水进行冲洗，分割，并且进行观察记录肝脏外形及其颜色。取适量肝组织中叶置于固定液中进行固定，剩余组织置于液氮中保存，备用。
1.2实验方法
1.2.1血清中AKP、ALT、AST活力水平的测定
血样室温静置2h，4℃冰箱静置过夜，离心转速3000rpm，离心15min，吸出上清，吸出时勿接触到底部的沉淀，将血清分装后用于检测各指标。具体步骤按照商业试剂盒说明书进行操作。
1.2.2肝组织GSH-PX和SOD活力水平及MDA含量的测定
取小鼠肝脏组织0.1g左右，组织重量之间差别小于0.05g，将称重好的组织置于2mL离心管中做好标记，每个离心管中加入1mL生理盐水，用电动组织匀浆器进行低温匀浆。振荡器震荡混匀后得到组织匀浆。后续具体步骤按照商业试剂盒说明书进行操作。
1.2.3小鼠肝脏HE染色以及肝脏天狼猩红染色
取新鲜小鼠肝脏，相同位置，适当大小置于组织固定液中，固定组织24h后，将肝脏换入新的固定液中。制作肝组织石蜡切片，进行HE以及天狼猩红染色。
1.3实验结果
1.3.1风柜斗草对MCD鼠粮饲喂的小鼠血清中AKP、ALT、AST活力水平的影响
根据图3结果可知：(1)通过血清AKP活力水平的检测结果可得出：1.MCD组的小鼠血清中AKP活力水平较MCS组有极显著差异升高了44.8％(P<0.01)；2.MCS组与MCS+400mg/Kg SNE组血清中AKP活力水平没有差异(P>0.05)；3.MCD+100mg/Kg SNE组、MCD+200mg/KgSNE组、MCD+400mg/Kg SNE组小鼠血清中的AKP活力水平相对于MCD组随剂量的增加有逐渐下降趋势，其中MCD+100mg/Kg SNE组下降13.1％(P>0.05)、MCD+200mg/Kg SNE组下降14.8％(P>0.05)、MCD+400mg/Kg SNE组下降20.9％(P<0.05)。
(2)通过血清ALT活力水平检测结果可得出：1.MCD组的小鼠血清中ALT活力水平较MCS组有极显著差异升高了4.2倍(P<0.01)；2.MCS组与MCS+400mg/Kg SNE组血清中ALT活力水平没有差异(P>0.05)；3.MCD+100mg/Kg SNE组、MCD+200mg/Kg SNE组、MCD+400mg/Kg SNE组小鼠血清中的ALT活力水平相对于MCD组随剂量的增加有逐渐下降趋势，其中MCD+100mg/Kg SNE组下降38.2％(P<0.05)、MCD+200mg/Kg SNE组下降58.1％(P<0.01)、MCD+400mg/KgSNE组下降63.1％(P<0.01)。
(3)通过血清AST活力水平检测结果可得出：MCD组与MCS组未见显著差异(P>0.05)，但MCD组的小鼠血清中AST活力水平较MCS组平均升高了40.5％，同时MCD+100mg/KgSNE组、MCD+200mg/Kg SNE组、MCD+400mg/Kg SNE组小鼠血清中的ALT活力水平相对于MCD组随剂量的增加有逐渐下降趋势，MCD+200mg/Kg SNE组下降4.7％、MCD+400mg/Kg SNE组下降14.4％。
1.3.2风柜斗草对MCD鼠粮饲喂的小鼠肝组织中GSH-PX和SOD活力水平及MDA含量的影响
根据图4结果可知：(1)通过肝组织GSH-PX活力水平检测结果可得出：1.MCD组的小鼠肝组织中GSH-PX活力水平较MCS组降低了30.3％(P<0.01)；2.MCS组与MCS+400mg/Kg SNE组肝组织中GSH-PX活力水平没有差异(P>0.05)；3.MCD+100mg/Kg SNE组的小鼠肝组织中GSH-PX活力水平相对于MCD组升高了35.2％(P<0.01)，MCD+200mg/Kg SNE组升高了35.9％(P<0.05)，MCD+400mg/Kg SNE组升高了12.1％(P>0.05)。
(2)通过肝组织MDA含量检测结果可得出：1.MCD组的小鼠肝组织中MDA含量较MCS组升高了33.2％(P<0.05)；2.MCS组与MCS+400mg/Kg SNE组肝组织中MDA含量没有差异(P>0.05)；3.MCD+100mg/Kg SNE组的小鼠肝组织中MDA含量相对于MCD组降低了28.9％(P<0.05)，中MCD+200mg/Kg SNE组降低了37.6％(P<0.01)，MCD+400mg/Kg SNE组降低了29.7％(P<0.05)。
(3)通过肝组织SOD活力水平检测结果可得出：MCD组与MCS组未见显著差异(P>0.05)，MCD组小鼠肝组织中SOD活力水平的平均水平较MCS组有所下降，降低了15.3％(P>0.05)，同时MCD+100mg/Kg SNE组、MCD+200mg/Kg SNE组、MCD+400mg/Kg SNE组小鼠肝组织中SOD活力水平均高于MCD组。
1.3.3风柜斗草对MCD鼠粮饲喂的小鼠肝组织切片的影响
根据图5、6、7的切片对比图可知：(1)肝脏切片HE染色发现：对照MCS组的小鼠肝脏切片，MCD组肝细胞中出现大量脂质积聚，脂质聚集导致细胞核向一侧偏移，肝静脉索周围细胞结构参差不齐，可见炎性细胞浸润及炎症簇；MCS+400mg/Kg SNE组中肝静脉索周围细胞结构排列整齐，细胞内无明显脂质出现，这说明MCS+400mg/Kg SNE组不会对小鼠的肝脏造成影响；MCD+100mg/Kg SNE组对比MCD组，肝细胞中积聚减少；MCD+200mg/Kg SNE、MCD+400mg/Kg SNE组对比MCD组，肝细胞中脂质积聚显著减少，较少见炎症簇，肝脏细胞结构整齐边界清楚。
(2)肝脏切片天狼猩红染色发现：对照MCS组的小鼠肝脏切片，MCD组小鼠肝脏纤维化明显；MCS+400mg/Kg SNE组中肝细胞排列紧密整齐，未见异常情况，这说明MCS+400mg/KgSNE组不会对小鼠的肝脏造成影响；MCD+100mg/Kg SNE组、MCD+200mg/Kg SNE组、MCD+400mg/Kg SNE组小鼠肝脏切片中纤维化较MCD组都有明显改善，且随剂量的增加纤维化改善越明显，在MCD+400mg/Kg SNE组中已未见明显的纤维化。
1.4结论
本实施例以MCD饲料饲喂C57BL/6小鼠构建肝脏脂质沉积症的动物模型，模型组小鼠肝脏出现严重的脂肪变性、炎症反应以及肝脏纤维化，同时用水煮醇沉得到的风柜斗草提取物进行干预治疗后，发现可以显著改善小鼠血清ALT、AKP活力水平，显著改善肝组织GSH-PX活力水平及MDA含量，显著改善肝组织的脂肪变性、炎症反应以及肝脏纤维化。
实施例3
风柜斗草提取物应用于临床猫肝脂沉积症
1.1实验材料
1.1.1临床病例
对临床上被确诊为肝脂沉积综合症且经主人同意以本发明的风柜斗草中兽药制剂为保肝护肝药物进行治疗的六例猫肝脂沉积综合症的猫咪收集其病例信息进行统计分析。
1.1.2实验仪器
自动血液生化分析仪、全自动血液常规分析仪、全身彩色多普勒超声仪。
1.2实验方法
1.2.1诊断
(1)病例资料：根据病例资料及病史，进行初步判断。
(2)实验室检查：病猫进行血常规检查、血液生化检查、血凝检查和B超检查(六例肝脂沉积症的猫咪具体检查结果见表3)。
(3)确诊：多数猫有肥胖史，近期或一段时间内少食、厌食，大幅消瘦，脱水，黄疸，精神沉郁，被毛粗乱；肝功能指标升高、血糖可能升高且多数猫咪有贫血、凝血不良的情况；血液常规指标一般无特定变化，可能升高或正常；B超影像呈现出肝脏体积增大、实质回声增强、脉管结构不清，可能有门脉扩张，流速慢等情况(B超影像见图8)。
表3六例病例初次化验检查结果
B超影像可见：病例1，肝脏体积增大，轮廓钝圆，呈现弥漫性强回声。胆囊充盈，壁薄光滑，腔内容物回声不均匀，考虑胆泥。病例2，肝脏弥散性回声增强，回声强度与镰状脂肪以及脾脏回声相似，脉管结构欠清晰。病例3，肝脏体积增大，边缘钝圆，弥散性回声增强。病例4，肝脏体积增大，弥散性回声增强，脉管结构欠清晰。病例5，肝脏体积增大，轮廓钝圆，呈现弥漫性强回声且有散在性强回声灶，脉管结构欠清晰。病例6，肝脏体积增大，肝脏包膜增厚回升较强，肝内弥散性回声增强。
1.2.2治疗
治疗方案需根据病例临床症状以及实验室检测结果进行不同调整，现总结如下：
(1)埋置静脉留置针。
(2)纠正脱水及离子紊乱补液首选复方氯化钠，同时根据离子检测情况进行相应的补充。
(3)给予静脉营养及能量补充，如含有丰富氨基酸的注射液、ATP、COA、维生素等。
(4)根据病例的血凝情况给与皮下注射维生素K。
(5)血常规检查有白细胞高的病例通过给予头孢、替硝唑等抗生素控制继发感染。
(6)对有较严重呕吐症状的病例根据情况给与甲氧氯普胺、马罗匹坦、格拉司琼等止吐药物。
(7)病例脱水情况得到缓解后，根据病例情况选择适当的麻醉或镇静药物静脉推注进行鼻饲管的放置。
(8)饲管放置后开始经饲管给与流食以及各种需要补充的营养物质；同时给与保肝药物，本实验中六例病例只给予风柜斗草中兽药制剂进行保肝护肝的治疗(治疗剂量为80mg/Kg经饲管给药，每日两次随流食共同饲喂)
1.3实验结果
1.3.1血液指标
根据图9可见：随之治疗的逐渐进行，所有的六例病例初诊时的不正常指标在最后一次检查时都基本恢复到正常值区间内，虽然部分指标在治疗过程中出现波动，考虑这有可能跟机体对各种酶和物质的代谢周期不同有关。部分病例血糖指标的不稳定性可能与猫咪采血时产生的应激性高血糖有关。
1.3.2B超影像
根据图9可见：通过对比六例病例初诊和治疗后的影像学印象，可以看出六例病例在影像学上都有了不同程度的改善：肝脏的回声较初诊时均匀；胆囊内的不均匀物质已不可见；脉管结构较初诊时清晰可见；肝脏大小较初诊时有所改善。
1.3.3临床症状
经治疗六例猫脂肪肝病例呕吐，黄疸，凝血不良、厌食等临床症状基本消失，精神好转，被毛粗糙程度改善，食欲良好，且六例猫平均治疗时间在一个月左右，治疗时间较用其他保肝药物相比有一定的缩短。
1.4结论
本实施例研究结果表明风柜斗草提取对临床猫肝脂沉积症有治疗作用且作用效果良好，并通过对风柜斗草提取物应用于临床猫肝脂沉积症的初步探索，初步确定治疗剂量，为后续开展规模性临床实验提供基础及依据。
实施例4
一种治疗犬猫肝脂沉积症的中兽药制剂，其由以下原料组成(以5Kg体重犬猫计)：
风柜斗草提取物 250mg；
蛋氨酸 15mg；
胆碱 15mg；
VB1 5mg；
VB2 5mg；
VB6 5mg；
VB12 5μg。
将风柜斗草提取物和蛋氨酸、胆碱、VB1、VB2、VB6、VB12按上述比例混合，得到所述治疗犬猫肝脂沉积症的中兽药制剂。
实施例5
一种治疗犬猫肝脂沉积症的中兽药制剂，其由以下原料组成(以5Kg体重犬猫计)：
风柜斗草提取物 375mg；
蛋氨酸 20mg；
胆碱 20mg；
VB1 5mg；
VB2 5mg；
VB6 5mg；
VB12 5μg。
将风柜斗草提取物和蛋氨酸、胆碱、VB1、VB2、VB6、VB12按上述比例混合，得到所述治疗犬猫肝脂沉积症的中兽药制剂。
实施例6
一种治疗犬猫肝脂沉积症的中兽药制剂，其由以下原料组成(以5Kg体重犬猫计)：
风柜斗草提取物 500mg；
蛋氨酸 25mg；
胆碱 25mg；
VB1 10mg；
VB2 10mg；
VB6 10mg；
VB12 5μg。
将风柜斗草提取物和蛋氨酸、胆碱、VB1、VB2、VB6、VB12按上述比例混合，得到所述治疗犬猫肝脂沉积症的中兽药制剂。
Claims (2)
1.一种治疗犬猫肝脂沉积症的中兽药制剂的制备方法，其特征在于：
所述中兽药制剂由以下重量份的原料组成：
风柜斗草提取物250-500 mg；
蛋氨酸 20 mg；
胆碱 20 mg；
VB1 5 mg；
VB2 5 mg；
VB6 5 mg；
VB12 5μg；
所述制备方法包括以下步骤：
1）将风柜斗草粉碎过 50 目筛，取风柜斗草粉 100 g，用20-25 倍水浸泡升温至 70℃后超声萃取 2-2.5 h，抽滤泵抽滤收集一次滤液；滤渣用20-25倍水重复操作一次，收集二次滤液；合并一次滤液和二次滤液并负压旋转蒸发浓缩至 10-15 mL，冷却至室温，加入无水乙醇至乙醇含量为70 %，抽滤泵抽滤得上清，将上清负压旋转蒸发浓缩，冷冻干燥，即得到风柜斗草提取物；
2）将风柜斗草提取物和蛋氨酸、胆碱、VB1、VB2、VB6、VB12按比例混合，得到所述治疗犬猫肝脂沉积症的中兽药制剂。
2.根据权利要求1所述的制备方法得到的中兽药制剂在制备治疗犬猫肝脂沉积症的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110517975.1A CN113171424B (zh) | 2021-05-12 | 2021-05-12 | 一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110517975.1A CN113171424B (zh) | 2021-05-12 | 2021-05-12 | 一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113171424A CN113171424A (zh) | 2021-07-27 |
| CN113171424B true CN113171424B (zh) | 2022-05-31 |
Family
ID=76929890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110517975.1A Active CN113171424B (zh) | 2021-05-12 | 2021-05-12 | 一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113171424B (zh) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279744A (zh) * | 2019-06-27 | 2019-09-27 | 龙岩学院 | 一种保肝护肝复方中药制剂及其制备方法 |
-
2021
- 2021-05-12 CN CN202110517975.1A patent/CN113171424B/zh active Active
Non-Patent Citations (1)
| Title |
|---|
| 王玥文等.风柜斗草提取物通过调控脂质代谢改善小鼠肝脂质沉积症.《畜牧兽医学报》.2022,第53卷(第3期),第925-937页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113171424A (zh) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112057546A (zh) | 一种蜂胶灵芝孢子粉组合物及其制备方法和应用 | |
| CN105209028B (zh) | 治疗脂肪肝疾病的方法 | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN102114170B (zh) | 防治心肌缺血再灌注损伤的中药组合物及其制备方法 | |
| CN113171424B (zh) | 一种治疗犬猫肝脂沉积症的中兽药制剂及其制备方法 | |
| CN105713942A (zh) | 西兰花多肽活性组分及其制备方法和应用 | |
| CN106036173A (zh) | 一种春季用雏鸭饲料添加剂 | |
| CN108567914A (zh) | 一种具有改善睡眠作用的中药制剂及其制备方法和应用 | |
| CN106309546A (zh) | 治疗糖尿病肾病的提取物 | |
| CN115089622A (zh) | 芹菜外泌体组合物及其制备方法与应用 | |
| CN102614247A (zh) | 小豆(菜豆、四棱豆)提取物在制备抗糖尿病药物中的应用 | |
| CN1081465C (zh) | 一种治疗冠心病心绞痛的红景天注射剂的制备方法 | |
| CN109771454A (zh) | 桦树茸提取物在制备治疗和/或预防高脂饮食致肝损伤相关疾病的制剂中的用途 | |
| CN105111328A (zh) | 一种硒酸酯化梭柄松苞菇多糖的制备方法 | |
| TWI620815B (zh) | 用於改善非酒精性脂肪變性肝炎的樟芝菌絲體發酵物、其製備方法及其用途 | |
| CN1733055A (zh) | 胡芦巴提取物及其制备方法和应用 | |
| CN104510884A (zh) | 一种治疗心脑血管疾病的复方中药制剂 | |
| CN204374176U (zh) | 一种天然过敏原检测剂制备仪 | |
| CN109294984A (zh) | 一种体内高效扩增nk细胞的香菇多糖胶囊及其制备方法 | |
| CN1355022A (zh) | 枸杞多糖在制备治疗脂肪肝药物中的应用 | |
| CN102784170B (zh) | 蜂胶抗粉尘螨过敏活性物质的分离方法 | |
| CN1623557A (zh) | 金耳菌丝体多糖降低血糖和血脂方面的应用 | |
| CN115645449A (zh) | 一种双辅料酒蜜制山萸肉炮制方法及应用 | |
| CN114767705A (zh) | 玉竹多糖在制备治疗肺损伤的药物中的应用 | |
| CN1274339C (zh) | 氨杞制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |